Physician profile
Albert J Staab
NPI 1306880257
$1,528.30
in general payments reported to CMS, 2019-2025
13 companies · $544 in 2025
The $544 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.14 · 2021: $128 · 2022: $319 · 2023: $267 · 2024: $228 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $387.79 | 2020-2025 | Total30, Dailies Total1, Precision 7 |
| Bausch & Lomb Americas INC. | $360.66 | 2022-2025 | Infuse, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $360.39 | 2020-2025 | Acuvue |
| Abb Con-Cise Optical Group LLC | $145.17 | 2021-2025 | Contact Lens |
| Medline Industries LP | $69.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $41.27 | 2022-2023 | |
| Coopervision INC. | $38.82 | 2021-2022 | |
| Amgen INC. | $32.08 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $29.38 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $16.33 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $16.17 | 2025 | |
| Horizon Therapeutics Plc | $16.09 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Staab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.